The pioneer of precision medicine and the promoter of the modernization of traditional Chinese Medicine

Lizhu Pharmaceutical Group Co., Ltd (hereinafter referred to as "Lizhu Pharmaceutical Group") was founded in 1985 After 32 years of pioneering, Lizhu Pharmaceutical Group has developed from a small iron house workshop to a large pharmaceutical group with 32 wholly-owned, holding and joint venture companies, integrating product research and development, production and sales For many years, Lizhu Pharmaceutical Group has been adhering to the business philosophy of people-oriented, fine business and quality, aiming to provide domestic leading and international first-class specialty drugs, and taking the development and layout of "precision medical" related businesses as its vision In 1993, a and B shares of Lizhu medical group were listed successively; in 2014, Lizhu medical group became the first listed company in the industry to complete a + H shares At present, 83% of the group's employees have higher education level, with strong technical force, excellent equipment and advanced technology With the continuous improvement and improvement of the quality system, the rapid growth of sales, the continuous expansion of production capacity, and the acceleration of the construction of new factories, Lizhu Pharmaceutical Group has gradually grown into a leading domestic and world-class modern pharmaceutical leading enterprise With the joint efforts of all employees, Lizhu group fosters the ability of independent innovation through the establishment of development, production, learning and research cooperation of closed R & D institutions The group has developed and cooperated with Beijing University of traditional Chinese medicine, Shenyang Pharmaceutical University, Chinese University of Hong Kong, Hong Kong Baptist University, Sun Yat sen University and Jinan University to develop the national second-class new drug Shenqi Fuzheng injection, with an output value of US $2.1 billion in 2016, becoming the largest traditional Chinese medicine in Guangdong Province in terms of market sales Among them, the group's pharmaceutical R & D cooperation with Professor Cao Yun's team has achieved good economic and social benefits, which is a typical example of the group's industry university research cooperation In recent years, through building innovation platform to strengthen collaborative innovation, Lizhu Pharmaceutical Group has won many domestic industry Honors: in 2011, it was rated as the top 20 most competitive pharmaceutical listed companies in China; in 2012, it was rated as the top 10 best listed enterprise governance; in 2013, it was rated as the top 10 listed enterprise investment value; in 2014-2016, it was rated as the most famous brand value of China 500 in a row Strong enterprises In 2016, Lizhu pharmaceutical group moved from Xiangzhou District, Zhuhai City to Lizhu Industrial Park, Jinwan District Lizhu Industrial Park covers an area of 427000 square meters, with a total investment of about 2 billion yuan It is an international first-class modern pharmaceutical production base built in accordance with FDA and EU standards Its excellent hardware equipment and fully automatic intelligent operation are in the world's leading level Especially in recent years, Lizhu Pharmaceutical Group, driven by scientific research and innovation, has established McAb Biotechnology Co., Ltd., established a domestic and foreign biomedical R & D team with national thousand talents program expert review and Guangdong provincial leading talents as the backbone, and built a "leading domestic and international track" McAb biomedical R & D platform In 2015, the group followed the pace of national development, distributed "precision medicine", and established shengmei company and gene testing company According to the development plan, Lizhu Pharmaceutical Group will achieve the strategic target of 10 billion sales in 2017 There are more than 400 varieties, 18 patented products and 21 independent innovative products, such as chemical medicine, Chinese patent medicine, diagnostic reagent, etc The varieties cover various categories such as chemical medicine, traditional Chinese medicine, biological products, etc., involving many treatment fields such as digestive system medicine, cardiovascular system medicine, respiratory system medicine, antipyretic and analgesic drugs and blood system medicine Among them, Shenqifuzheng injection, iprazole and industrialization of traditional Chinese medicine have won the first prize of Guangdong Provincial Science and technology progress, and the original research drug iprazole has won the second prize of national science and technology progress The technical invention and application of antiviral Granules against new infectious diseases won the first prize of science and technology of Chinese Academy of traditional Chinese medicine in 2014 According to the pharmaceutical intelligence data, from 2013 to now, Lizhu Pharmaceutical Group (including its subsidiaries) has obtained 38 clinical and production application acceptance numbers The annual application acceptance is shown in the figure below Figure 1 annual clinical and production application of Lizhu Pharmaceutical Group (including subsidiaries): in Figure 1, there are 10 acceptance numbers of cxhl, involving 10 molecular entities, of which 7 have been approved for clinical application There are 5 acceptance numbers of cxhs, involving 2 acceptance numbers of cxsl, 4 acceptance numbers of cxsl, of which 3 have been approved, 1 acceptance number of cxss has been approved, 18 acceptance numbers of national standardized drug report, involving 12 molecular entities, of which 6 acceptance numbers have been approved for clinical patent application and authorization According to incomplete statistics, by the end of 2016, Lizhu Pharmaceutical Group (including its subsidiaries) had applied for 255 Chinese invention patents, including 152 authorized patents Every year, patent applications for invention have a high authorization rate (Figure 2) The technical types of patents cover many fields (Table 1) In addition, Lizhu Pharmaceutical Group (including its subsidiaries) has applied for 11 PCT patents Figure 2 Patent application and authorization of Lizhu Pharmaceutical Group (including its subsidiaries) in China Table 1 technology type distribution of Lizhu Pharmaceutical Group (including subsidiaries) applying for Chinese invention patent note: the "technology type" is determined according to claim 1 Original statement: This article is the original manuscript of yaozhi.com, welcome to reprint, reprint please indicate the source and author, thank you!